Prelude Capital Management’s Medifast MED Stock Holding History

Prelude Capital Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-200	Closed	-$22K	–	1794
2019 Q4	$22K	Buy	+200	New	+$19.4K	﹤0.01%	1567

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prelude Capital Management's MED Position: Q4 2023 in Review

Prelude Capital Management sold out of Medifast (MED) in Q4 2023, closing a stake of 2,785 shares — an estimated $208K sold.

Prelude Capital Management first reported a position in MED in Q3 2013 and held it in 24 quarters. The position peaked at $2.48M in Q4 2019. 216 funds tracked by Wall St. Rank hold MED as of Q4 2023.

Prelude Capital Management reported no remaining Medifast position as of Q4 2023 after selling out during the quarter.
Prelude Capital Management sold 2,785 Medifast shares in Q4 2023, an estimated $208K.
Prelude Capital Management first reported a position in Medifast in Q3 2013 and held it in 24 quarters.
Prelude Capital Management's Medifast position peaked at $2.48M in Q4 2019.
216 funds tracked by Wall St. Rank held Medifast as of Q4 2023.

Based on Prelude Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.